サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1429625

リツキシマブバイオシミラーの世界市場レポート 2024

Rituximab Biosimilars Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 250 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
リツキシマブバイオシミラーの世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 250 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

リツキシマブバイオシミラーの市場規模は、今後数年間で急速に成長すると予想されています。 2028年には12.8%の年間複合成長率（CAGR）で48億9,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、人口の高齢化、ヘルスケアへのアクセスの改善、慢性疾患の有病率の増加に関連している可能性があります。この期間の注目すべき動向としては、バイオシミラー医薬品の開発に関する最新のFDA規制を活用すること、新薬開発のための研究開発イニシアチブを拡大するために主要企業と戦略的パートナーシップや協力協定を締結すること、効果的な医薬品を開発するための研究開発活動に多額の投資を行うこと、革新的なバイオシミラーが挙げられます。

非ホジキンリンパ腫（NHL）の発生率の増加は、リツキシマブバイオシミラー市場の拡大に寄与すると予想されます。非ホジキンリンパ腫、またはリンパ腫は、体の免疫系の不可欠な構成要素である白血球とリンパ球に由来するがんの一種です。米国がん協会によると、NHLは米国で最も蔓延しているがんであり、全がんの約4%を占めています。米国では、2021年に推定81,560人（男性45,630人、女性35,930人）がNHLの診断を受けると予想されています。その結果、非ホジキンリンパ腫の症例の増加により、予測期間を通じてリツキシマブバイオシミラーの需要が高まると予測されています。

自己免疫疾患の有病率の急増により、将来、リツキシマブバイオシミラー市場の成長が促進されると見られています。自己免疫疾患には、体の免疫系が健康な組織を異物であるという誤解のもとに攻撃する疾患が含まれます。 リツキシマブバイオシミラーは、特定のB細胞を標的とすることで自己免疫疾患の治療に応用され、それによって炎症や自己免疫反応を軽減します。たとえば、2021年7月の時点で、米国では140万人がクローン病または潰瘍性大腸炎に罹患しており、100万人が狼瘡と診断されているとクリーブランドクリニックは報告しています。さらに、自己免疫疾患は、64歳までのすべての年齢層の女性の死因のトップ 10にランクされています。したがって、自己免疫疾患の有病率の急増は、リツキシマブバイオシミラー市場の成長の重要な原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のリツキシマブバイオシミラー市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 皮下
  • 静脈内
  • 分子タイプ
  • 世界のリツキシマブバイオシミラー市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 非ホジキンリンパ腫
  • 慢性リンパ性白血病
  • 関節リウマチ
  • その他の用途
  • 世界のリツキシマブバイオシミラー市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • オンライン薬局
  • 小売薬局
  • その他の直接流通チャネル

第7章 地域および国の分析

  • 世界のリツキシマブバイオシミラー市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界のリツキシマブバイオシミラー市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • リツキシマブバイオシミラー市場の競合情勢
  • リツキシマブバイオシミラー市場の企業プロファイル
    • Cellitron
    • Novartis AG
    • Pfizer
    • BIOCAD
    • Shanghai Henlius Biotech Inc.

第31章 その他の大手および革新的な企業

  • Sandoz
  • Innovent Biologics Inc.
  • Sinocelltech
  • Cadila Pharmaceuticals
  • Hetero Drugs Limited
  • Dr. Reddy's Laboratories
  • Shanghai Fosun Pharmaceutical（Group）Co. Ltd.
  • Reliance Life Sciences India
  • Zenotech Laboratories
  • NAPP Pharmaceuticals Limited
  • Mundipharma Deutschland GmbH &Co. KG
  • Celltrion
  • Biocad
  • MABION SA
  • Janssen Pharmaceutical

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r14596

A rituximab biosimilar is a chimeric monoclonal antibody designed to target the B cell-specific protein CD20 within the immune system. This monoclonal antibody, rituximab, is effective in eliminating B cells, making it a valuable treatment for conditions characterized by an excess, overactive, or otherwise abnormal presence of B cells.

Rituximab biosimilars can be administered through various routes, including subcutaneous, intravenous, and molecular methods. Intravenous therapy involves the direct delivery of fluids, medications, and nutrients into a patient's vein. The applications of rituximab biosimilars span across medical conditions such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and others. These biosimilars are distributed through different channels, including hospital pharmacies, online pharmacies, retail pharmacies, and various direct distribution channels.

The rituximab biosimilars market research report is one of a series of new reports from The Business Research Company that provides rituximab biosimilars market statistics, including rituximab biosimilars industry global market sizes, regional shares, competitors with a rituximab biosimilars market share, detailed rituximab biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the rituximab biosimilars industry. This rituximab biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The rituximab biosimilars market size has grown rapidly in recent years. It will grow from $2.66 billion in 2023 to $3.02 billion in 2024 at a compound annual growth rate (CAGR) of 13.3%. The expansion observed in the historical period can be ascribed to government initiatives, heightened healthcare spending, growth in research and development expenditure for biopharmaceuticals, the cost-effectiveness of biosimilars, and the burgeoning growth in emerging markets.

The rituximab biosimilars market size is expected to see rapid growth in the next few years. It will grow to $4.89 billion in 2028 at a compound annual growth rate (CAGR) of 12.8%. The anticipated growth in the forecast period can be linked to the aging population, improved access to healthcare, and an increasing prevalence of chronic diseases. Noteworthy trends during this period involve capitalizing on updated FDA regulations for the development of biosimilar drugs, forging strategic partnerships and collaboration agreements with major players to broaden research and development initiatives for new drug developments, and making substantial investments in research and development activities to create effective and innovative biosimilars.

The increasing incidence of non-Hodgkin's lymphoma (NHL) is anticipated to contribute to the expansion of the rituximab biosimilars market. Non-Hodgkin's lymphoma, or lymphoma, is a form of cancer that originates in white blood cells and lymphocytes, integral components of the body's immune system. According to the American Cancer Society, NHL ranks as the most prevalent cancer in the USA, constituting approximately 4% of all cancers. In the United States, an estimated 81,560 individuals (45,630 men and 35,930 women) were expected to receive a NHL diagnosis in 2021. Consequently, the increasing instances of non-Hodgkin's lymphoma are projected to result in a heightened demand for rituximab biosimilars throughout the forecast period.

The upsurge in the prevalence of autoimmune diseases is poised to drive the growth of the rituximab biosimilars market in the future. Autoimmune diseases encompass disorders wherein the body's immune system attacks healthy tissues under the misconception that they are foreign. Rituximab biosimilars find application in treating autoimmune diseases by targeting specific B cells, thereby mitigating inflammation and autoimmune responses. For example, as of July 2021, the Cleveland Clinic reported that in the United States, 1.4 million people are affected by Crohn's disease or ulcerative colitis, and one million are diagnosed with lupus. Moreover, autoimmune diseases rank among the top 10 causes of death for women across all age groups up to 64. Hence, the surge in autoimmune diseases' prevalence is a significant driver of the rituximab biosimilars market's growth.

Companies in the biosimilars industry continue to prioritize new product development through collaborations with industry peers. This trend is particularly evident in the rituximab biosimilars market. An example of such collaboration occurred in July 2023 when Dr. Reddy's Laboratories partnered with Fresenius Kabi to commercialize their proposed rituximab biosimilar in the US. The goal of this collaboration is to introduce a more affordable and accessible biosimilar version of rituximab to the market, offering an alternative treatment option for patients. The introduction of a biosimilar rituximab in the United States has the potential to enhance access to this crucial treatment for various conditions, including rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, pemphigus vulgaris, granulomatosis with polyangiitis, and microscopic polyangiitis.

Key players in the rituximab biosimilars market are actively engaged in the development of FDA-approved rituximab biosimilars to establish a competitive advantage. A rituximab biosimilar that receives FDA approval is used in the treatment of specific immune-related conditions and malignancies. For instance, in June 2022, the US-based biopharmaceutical company Amgen Inc. obtained FDA approval for RIABNI (rituximab-arrx), a biosimilar to Rituxan (rituximab). RIABNI is the only FDA-approved rituximab biosimilar for all available Rituxan indications, encompassing Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis), Microscopic Polyangiitis (MPA), and moderately to severely active rheumatoid arthritis (RA) with an inadequate response to TNF antagonist therapies.

Major companies operating in the rituximab biosimilars market report are Cellitron, Novartis AG, Pfizer, BIOCAD, Shanghai Henlius Biotech Inc., Sandoz, Innovent Biologics Inc., Sinocelltech, Cadila Pharmaceuticals, Hetero Drugs Limited, Dr. Reddy's Laboratories, Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Reliance Life Sciences India, Zenotech Laboratories, NAPP Pharmaceuticals Limited, Mundipharma Deutschland GmbH & Co. KG, Celltrion, Biocad, MABION S.A., Janssen Pharmaceutical, Amgen, Teva Pharmaceuticals, Celltrion Healthcare, Coherus BioSciences, Innovent Biologics, Mylan, Aryogen Biopharma, TR-Pharm, Hikma Pharmaceuticals plc.

North America was the largest region in the rituximab biosimilars market in 2023. Middle East is expected to be the fastest-growing region in the rituximab biosimilars market report during the forecast period. The regions covered in the rituximab biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the rituximab biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The rituximab biosimilar market consists of sales of mabthera, truxima, ruxience, or rixathon. Values in this market are ''factory gate values,'' that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rituximab Biosimilars Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rituximab biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rituximab biosimilars? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rituximab biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Route Of Administration: Subcutaneous; Intravenous; Molecular Type
  • 2) By Application: Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia; Rheumatoid Arthritis; Other Applications
  • 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Mail Order
  • Companies Mentioned: Cellitron; Novartis AG; Pfizer; BIOCAD; Shanghai Henlius Biotech Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Rituximab Biosimilars Market Characteristics

3. Rituximab Biosimilars Market Trends And Strategies

4. Rituximab Biosimilars Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Rituximab Biosimilars Market Size and Growth

  • 5.1. Global Rituximab Biosimilars Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Rituximab Biosimilars Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Rituximab Biosimilars Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Rituximab Biosimilars Market Segmentation

  • 6.1. Global Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Subcutaneous
  • Intravenous
  • Molecular Type
  • 6.2. Global Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Non-Hodgkin's Lymphoma
  • Chronic Lymhocytic Leukemia
  • Rheumatoid Arthritis
  • Other Applications
  • 6.3. Global Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Other Direct Distribution Channels

7. Rituximab Biosimilars Market Regional And Country Analysis

  • 7.1. Global Rituximab Biosimilars Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Rituximab Biosimilars Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Rituximab Biosimilars Market

  • 8.1. Asia-Pacific Rituximab Biosimilars Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Rituximab Biosimilars Market

  • 9.1. China Rituximab Biosimilars Market Overview
  • 9.2. China Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Rituximab Biosimilars Market

  • 10.1. India Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Rituximab Biosimilars Market

  • 11.1. Japan Rituximab Biosimilars Market Overview
  • 11.2. Japan Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Rituximab Biosimilars Market

  • 12.1. Australia Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Rituximab Biosimilars Market

  • 13.1. Indonesia Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Rituximab Biosimilars Market

  • 14.1. South Korea Rituximab Biosimilars Market Overview
  • 14.2. South Korea Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Rituximab Biosimilars Market

  • 15.1. Western Europe Rituximab Biosimilars Market Overview
  • 15.2. Western Europe Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Rituximab Biosimilars Market

  • 16.1. UK Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Rituximab Biosimilars Market

  • 17.1. Germany Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Rituximab Biosimilars Market

  • 18.1. France Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Rituximab Biosimilars Market

  • 19.1. Italy Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Rituximab Biosimilars Market

  • 20.1. Spain Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Rituximab Biosimilars Market

  • 21.1. Eastern Europe Rituximab Biosimilars Market Overview
  • 21.2. Eastern Europe Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Rituximab Biosimilars Market

  • 22.1. Russia Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Rituximab Biosimilars Market

  • 23.1. North America Rituximab Biosimilars Market Overview
  • 23.2. North America Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Rituximab Biosimilars Market

  • 24.1. USA Rituximab Biosimilars Market Overview
  • 24.2. USA Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Rituximab Biosimilars Market

  • 25.1. Canada Rituximab Biosimilars Market Overview
  • 25.2. Canada Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Rituximab Biosimilars Market

  • 26.1. South America Rituximab Biosimilars Market Overview
  • 26.2. South America Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Rituximab Biosimilars Market

  • 27.1. Brazil Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Rituximab Biosimilars Market

  • 28.1. Middle East Rituximab Biosimilars Market Overview
  • 28.2. Middle East Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Rituximab Biosimilars Market

  • 29.1. Africa Rituximab Biosimilars Market Overview
  • 29.2. Africa Rituximab Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Rituximab Biosimilars Market Competitive Landscape And Company Profiles

  • 30.1. Rituximab Biosimilars Market Competitive Landscape
  • 30.2. Rituximab Biosimilars Market Company Profiles
    • 30.2.1. Cellitron
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Novartis AG
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Pfizer
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. BIOCAD
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Shanghai Henlius Biotech Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Rituximab Biosimilars Market Other Major And Innovative Companies

  • 31.1. Sandoz
  • 31.2. Innovent Biologics Inc.
  • 31.3. Sinocelltech
  • 31.4. Cadila Pharmaceuticals
  • 31.5. Hetero Drugs Limited
  • 31.6. Dr. Reddy's Laboratories
  • 31.7. Shanghai Fosun Pharmaceutical (Group) Co. Ltd.
  • 31.8. Reliance Life Sciences India
  • 31.9. Zenotech Laboratories
  • 31.10. NAPP Pharmaceuticals Limited
  • 31.11. Mundipharma Deutschland GmbH & Co. KG
  • 31.12. Celltrion
  • 31.13. Biocad
  • 31.14. MABION S.A.
  • 31.15. Janssen Pharmaceutical

32. Global Rituximab Biosimilars Market Competitive Benchmarking

33. Global Rituximab Biosimilars Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Rituximab Biosimilars Market

35. Rituximab Biosimilars Market Future Outlook and Potential Analysis

  • 35.1 Rituximab Biosimilars Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Rituximab Biosimilars Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Rituximab Biosimilars Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer